Biogen discontinuing natalizumab for stroke after Phase IIb miss

By Chris Lieu | Feb 7, 2018 | 8:34 PM GMT

Biogen Inc. (NASDAQ:BIIB) discontinued development of natalizumab to treat acute ischemic stroke after the drug missed the primary and secondary endpoints in the Phase IIb